Dhahri et al. describe practical methods for the scaled generation of mature hPSC-CMs and provide the first evidence that the transplantation of more mature cardiomyocytes yields better outcomes in vivo. Read more.
Funakoshi et al establish a differentiation strategy that promotes the specification, proliferation and maturation of compact ventricular cardiomyocytes from human pluripotent stem cells (hPSCs). Read more.
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — BlueRock Therapeutics […]
LEIDEN, NL, and CAMBRIDGE, MA, January 21, 2020 – Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes […]
Hartman and Laflamme provide a perspective on these studies and describe studies to directly reconstitute cardiomyocytes by ex vivo expansion from pluripotent stem cells. Read more.
Lee et al demonstrate the recapitulation of cardiomyocyte developmental pathways in producing and characterizing PSC derived cardiomyocytes and their authenticity when compared to adult tissue. Read more.
